# Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

> **NCT02635672** · PHASE1 · COMPLETED · sponsor: **Vincerx Pharma, Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** VIP152 (BAY 1251152)
- **DRUG:** VIP152 (BAY 1251152) 30 mg
- **DRUG:** Keytruda
- **DRUG:** VIP152 (BAY 1251152) 15 mg

## Key facts

- **NCT ID:** NCT02635672
- **Lead sponsor:** Vincerx Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635672, "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02635672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*